MedPath

Calcitriol

Generic Name
Calcitriol
Brand Names
Rocaltrol, Vectical
Drug Type
Small Molecule
Chemical Formula
C27H44O3
CAS Number
32222-06-3
Unique Ingredient Identifier
FXC9231JVH
Background

Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D, 1,25-dihydroxyvitamin D. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to Vitamin D3 (vitamin D3) in the skin, which is then converted to Calcifediol in the liver and kidneys. Calcifediol undergoes hydroxylation to form calcitriol via 1α-hydroxylase (CYP27B1) activity . Calcitriol is considered to be the most potent metabolite of vitamin D in humans . Renal production of calcitriol is stimulated in response to PTH, low calcium and low phosphate . Calcitriol plays a role in plasma calcium regulation in concert with parathyroid hormone (PTH) by enhancing absorption of dietary calcium and phosphate from the gastrointestinal tract, promoting renal tubular reabsorption of calcium in the kidneys, and stimulating the release of calcium stores from the skeletal system. In addition to promoting fatty acid synthesis and inhibiting lipolysis, calcitriol has been demonstrated to increase energy efficiency by suppressing UCP2 expression, which is modulated by signaling pathways of classical nuclear receptors (nVDR), where calcitriol acts as a natural ligand . There is also evidence that calcitriol modulates the action of cytokines and may regulate immune and inflammatory response, cell turnover, cell differentiation .

Administered orally and intravenously, calcitriol is commonly used as a medication in the treatment of secondary hyperparathyroidism and resultant metabolic bone disease, hypocalcemia in patients undergoing chronic renal dialysis, and osteoporosis. It is also available in topical form for the treatment of mild to moderate plaque psoriasis in adults. Calcitriol is marketed under various trade names including Rocaltrol (Roche), Calcijex (Abbott) and Decostriol (Mibe, Jesalis).

Indication

Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.

Associated Conditions
Hypocalcemia, Mild to Moderate Plaque Psoriasis, Osteodystrophy, Secondary Hyperparathyroidism (SHPT), Vitamin D Resistant Rickets

The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels

Phase 4
Conditions
Osteoporosis
Interventions
First Posted Date
2013-01-10
Last Posted Date
2013-01-10
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
88
Registration Number
NCT01765010
Locations
🇰🇷

Seoul National University Medical School, Seoul, Korea, Republic of

Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol

Phase 4
Completed
Conditions
Chronic Kidney Disease Stage 3
Interventions
First Posted Date
2012-12-12
Last Posted Date
2013-02-18
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
30
Registration Number
NCT01748396
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol

Phase 4
Terminated
Conditions
Kidney Failure
Secondary Hyperparathyroidism
Hyperphosphatemia
Hypercalcemia
Interventions
First Posted Date
2012-11-12
Last Posted Date
2023-11-07
Lead Sponsor
Winthrop University Hospital
Target Recruit Count
16
Registration Number
NCT01725113
Locations
🇺🇸

Winthrop University Hospital, Mineola, New York, United States

Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis

Phase 2
Completed
Conditions
Severe Sepsis or Septic Shock
Interventions
Drug: Placebo
First Posted Date
2012-09-21
Last Posted Date
2020-11-10
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
67
Registration Number
NCT01689441
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy

Phase 4
Conditions
Diabetic Nephropathy
Interventions
Drug: Placebo
First Posted Date
2012-08-27
Last Posted Date
2014-02-13
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
276
Registration Number
NCT01673204
Locations
🇰🇷

Seoul National University Boramae Medical Center, Seoul, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

The VALIDATE-D Study

Not Applicable
Completed
Conditions
Type 2 Diabetes
Obesity
Interventions
Drug: Placebo
First Posted Date
2012-07-06
Last Posted Date
2017-04-11
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
41
Registration Number
NCT01635062
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease

Phase 1
Completed
Conditions
Ovarian Cancer
Breast Cancer
Cancer
Cervical Cancer
Primary Peritoneal Carcinoma
Solid Tumor
Endometrial Cancer
Bone Sarcoma
Interventions
First Posted Date
2012-05-01
Last Posted Date
2017-04-25
Lead Sponsor
BPGbio
Target Recruit Count
30
Registration Number
NCT01588522
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai, Los Angeles, California, United States

Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2

Phase 4
Conditions
Chronic Kidney Disease Stage 1
Chronic Kidney Disease Stage 2
Interventions
Drug: placebo
First Posted Date
2012-03-22
Last Posted Date
2015-06-08
Lead Sponsor
Taixing People's Hospital
Target Recruit Count
300
Registration Number
NCT01561222
Locations
🇨🇳

Taixing People's Hospital, Taixing, Jiangsu, China

Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients

Phase 4
Conditions
Proteinuria
Interventions
Drug: Placebo
First Posted Date
2012-01-19
Last Posted Date
2012-04-10
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
240
Registration Number
NCT01512862
Locations
🇰🇷

SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of

🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba

Phase 4
Completed
Conditions
Pityriasis Alba
Interventions
First Posted Date
2011-07-06
Last Posted Date
2012-09-26
Lead Sponsor
Universidad Autonoma de San Luis Potosí
Target Recruit Count
39
Registration Number
NCT01388517
Locations
🇲🇽

Dermatology Department. Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosi, Mexico

© Copyright 2025. All Rights Reserved by MedPath